Cargando…

Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study

BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor (ICI)-associated myocarditis is a fatal immune-related adverse events (irAEs), which is prone to affecting multiple organ systems. Multi-organ irAEs have not been fully studied in ICI-associated myocarditis. Therefore, we aimed to explore the imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiaohong, Wang, Liqiang, Li, Yingqing, Xu, Yan, Wu, Jianhui, Lin, Xinqing, Lin, Wen, Mai, Qicong, Chen, Zhanhong, Zhang, Jiexia, Xie, Zhanhong, Qin, Yinyin, Liu, Ming, Lu, Mingjun, Luo, Bihui, Zhou, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340212/
https://www.ncbi.nlm.nih.gov/pubmed/35924238
http://dx.doi.org/10.3389/fimmu.2022.879900
_version_ 1784760351786532864
author Xie, Xiaohong
Wang, Liqiang
Li, Yingqing
Xu, Yan
Wu, Jianhui
Lin, Xinqing
Lin, Wen
Mai, Qicong
Chen, Zhanhong
Zhang, Jiexia
Xie, Zhanhong
Qin, Yinyin
Liu, Ming
Lu, Mingjun
Luo, Bihui
Zhou, Chengzhi
author_facet Xie, Xiaohong
Wang, Liqiang
Li, Yingqing
Xu, Yan
Wu, Jianhui
Lin, Xinqing
Lin, Wen
Mai, Qicong
Chen, Zhanhong
Zhang, Jiexia
Xie, Zhanhong
Qin, Yinyin
Liu, Ming
Lu, Mingjun
Luo, Bihui
Zhou, Chengzhi
author_sort Xie, Xiaohong
collection PubMed
description BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor (ICI)-associated myocarditis is a fatal immune-related adverse events (irAEs), which is prone to affecting multiple organ systems. Multi-organ irAEs have not been fully studied in ICI-associated myocarditis. Therefore, we aimed to explore the impact of multi-organ irAEs on ICI myocarditis in terms of clinical features, treatment, and prognosis. METHODS: This was a retrospective study. The clinical data of ICI myocarditis patients were collected from 6 hospitals in China. The risk factors and characteristics of pure myocarditis and multi-organ irAEs were analyzed. The overall survival (OS) after myocarditis was analyzed and univariate and multivariate regression analysis were performed. RESULTS: A total of 46 patients were analyzed in this study. Multi-organ irAEs were common (30/46, 65.2%) and prone to severe heart failure. The severe myocarditis was observed in 32 patients (69.6%). When myocarditis occurred, neutrophil to lymphocyte ratio, C-reactive protein, lactate dehydrogenase, interleukin (IL)-6, IL-10, creatine kinase, MB isoenzyme of creatine kinase, and brain natriuretic peptide increased from baseline, but absolute lymphocyte count decreased. Thymoma (B2/B3) was a risk factor for multi-organ irAEs. Heart failure and myocarditis were more severe in patients with multi-organ irAEs and require early corticosteroid therapy (<24 hours). Univariate analysis showed that age ≥ 60 years, myocarditis (grade 3-4), heart failure (grade 3-4), multi-organ irAEs, and severe myocarditis were associated with OS after myocarditis. After adjusting for other factors, heart failure (grade 3-4) was an independent risk factor for immune-related myocarditis (HR: 6.655, 95% CI: 1.539-28.770, p=0.011). CONCLUSION: Patients with ICI-associated myocarditis had multi-organ irAEs with a high incidence of severe myocarditis, mortality, and poor prognosis. Thymoma was prone to those patients with multiple organs involvement. Patients could benefit from early corticosteroid intervention. Heart failure (grade 3-4) was an independent risk factor for OS after myocarditis.
format Online
Article
Text
id pubmed-9340212
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93402122022-08-02 Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study Xie, Xiaohong Wang, Liqiang Li, Yingqing Xu, Yan Wu, Jianhui Lin, Xinqing Lin, Wen Mai, Qicong Chen, Zhanhong Zhang, Jiexia Xie, Zhanhong Qin, Yinyin Liu, Ming Lu, Mingjun Luo, Bihui Zhou, Chengzhi Front Immunol Immunology BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor (ICI)-associated myocarditis is a fatal immune-related adverse events (irAEs), which is prone to affecting multiple organ systems. Multi-organ irAEs have not been fully studied in ICI-associated myocarditis. Therefore, we aimed to explore the impact of multi-organ irAEs on ICI myocarditis in terms of clinical features, treatment, and prognosis. METHODS: This was a retrospective study. The clinical data of ICI myocarditis patients were collected from 6 hospitals in China. The risk factors and characteristics of pure myocarditis and multi-organ irAEs were analyzed. The overall survival (OS) after myocarditis was analyzed and univariate and multivariate regression analysis were performed. RESULTS: A total of 46 patients were analyzed in this study. Multi-organ irAEs were common (30/46, 65.2%) and prone to severe heart failure. The severe myocarditis was observed in 32 patients (69.6%). When myocarditis occurred, neutrophil to lymphocyte ratio, C-reactive protein, lactate dehydrogenase, interleukin (IL)-6, IL-10, creatine kinase, MB isoenzyme of creatine kinase, and brain natriuretic peptide increased from baseline, but absolute lymphocyte count decreased. Thymoma (B2/B3) was a risk factor for multi-organ irAEs. Heart failure and myocarditis were more severe in patients with multi-organ irAEs and require early corticosteroid therapy (<24 hours). Univariate analysis showed that age ≥ 60 years, myocarditis (grade 3-4), heart failure (grade 3-4), multi-organ irAEs, and severe myocarditis were associated with OS after myocarditis. After adjusting for other factors, heart failure (grade 3-4) was an independent risk factor for immune-related myocarditis (HR: 6.655, 95% CI: 1.539-28.770, p=0.011). CONCLUSION: Patients with ICI-associated myocarditis had multi-organ irAEs with a high incidence of severe myocarditis, mortality, and poor prognosis. Thymoma was prone to those patients with multiple organs involvement. Patients could benefit from early corticosteroid intervention. Heart failure (grade 3-4) was an independent risk factor for OS after myocarditis. Frontiers Media S.A. 2022-07-18 /pmc/articles/PMC9340212/ /pubmed/35924238 http://dx.doi.org/10.3389/fimmu.2022.879900 Text en Copyright © 2022 Xie, Wang, Li, Xu, Wu, Lin, Lin, Mai, Chen, Zhang, Xie, Qin, Liu, Lu, Luo and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Xie, Xiaohong
Wang, Liqiang
Li, Yingqing
Xu, Yan
Wu, Jianhui
Lin, Xinqing
Lin, Wen
Mai, Qicong
Chen, Zhanhong
Zhang, Jiexia
Xie, Zhanhong
Qin, Yinyin
Liu, Ming
Lu, Mingjun
Luo, Bihui
Zhou, Chengzhi
Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
title Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
title_full Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
title_fullStr Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
title_full_unstemmed Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
title_short Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
title_sort multi-organ immune-related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: a multi-center study
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340212/
https://www.ncbi.nlm.nih.gov/pubmed/35924238
http://dx.doi.org/10.3389/fimmu.2022.879900
work_keys_str_mv AT xiexiaohong multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT wangliqiang multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT liyingqing multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT xuyan multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT wujianhui multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT linxinqing multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT linwen multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT maiqicong multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT chenzhanhong multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT zhangjiexia multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT xiezhanhong multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT qinyinyin multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT liuming multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT lumingjun multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT luobihui multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy
AT zhouchengzhi multiorganimmunerelatedadverseeventisariskfactorofimmunecheckpointinhibitorassociatedmyocarditisincancerpatientsamulticenterstudy